Medicines for combined treatment of dermatomyositis and interstitial lung diseases according to cell cycles

Abstract

The invention belongs to the technical field of immunosuppressants for combined treatment of rheumatic autoimmune diseases and particularly relates to medicines for combined treatment of dermatomyositis and interstitial lung diseases according to cell cycles in the principle of cell dynamics. The medicines comprise components in parts by weight as follows: 250-500 mg of MMF (mycophenolate mofetil) and 200-400 mg of CTX (cyclophosphamide). The use method of the medicines is as follows: MMF is taken 250-500 mg a day; CTX is taken 200-400 mg every three weeks and 200-400 mg every six weeks, every nine weeks and every twelve weeks if the diseases are controlled. The medicines are selected according to the cell cycles, the medicine with a specific cell cycle and the medicine with a nonspecific cell cycle are combined, the combination efficiency is improved, the dosage of a single medicine is reduced, and side effects are reduced; CTX is delivered intermittently according to the cell cycles, so that marrow and other normal cells and tissue have time to recover, intermittent medicine delivery is the key to reduction of side effects, and the problem of drug resistance caused by single medicine delivery is solved.

Description

technical field [0001] The invention belongs to the technical field of combined treatment of autoimmune diseases with immunosuppressants, and specifically relates to a drug for combined treatment of dermatomyositis complicated with pulmonary interstitial lesions according to the principle of cell dynamics and cell cycle. Background technique [0002] Dermatomyositis (DM) is an autoimmune disease that mainly affects striated muscle and is characterized by inflammatory cell infiltration accompanied by muscle fiber degeneration and necrosis, and may be accompanied by various skin lesions. Clinically, it is characterized by symmetrical weakness of limb-girdle muscles, neck muscles, and pharyngeal muscles, often involving multiple organs including the lungs, and may also be accompanied by tumors and other connective tissue diseases. [0003] According to reports, lung involvement is the most common internal organ lesion in DM, and interstitial lung disease (interstitiallungdiseas...

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is mainly to provide a combination therapy that follows the cell cycle in view of the side effects such as abnormal liver function, gastrointestinal tract reaction, abnormal hematopoietic function and susceptibility to infection of existing immunosuppressants, and the single drug is easy to produce drug resistance. Drugs for Dermatomyositis Complicated with Pulmonary Interstitial Lesions